BioStem Technologies to Present at LD Micro Invitational, Highlighting Regenerative Medicine Advances
BioStem Technologies will present at the 16th Annual LD Micro Invitational, showcasing its proprietary allograft technologies and expanding presence in regenerative medicine.
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced today that its management will present at the 16th Annual LD Micro Invitational conference in Los Angeles, California. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET, and will be accessible via live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com.
The LD Micro Invitational is a key event for small-cap and micro-cap companies, providing a platform to connect with institutional investors, analysts, and industry professionals. BioStem's participation underscores its commitment to raising awareness about its advanced allograft solutions, which are derived from perinatal tissues and processed using proprietary technologies including BioRetain®, CryoTek®, and SteriTek®. These technologies are designed to preserve the natural properties of the tissues, enhancing their utility in clinical settings across multiple specialties.
BioStem's appearance at this conference is significant as it comes amid the company's expanding commercial footprint and growing portfolio of products. The company's allografts are used by clinicians in a wide range of applications, and its quality management system has been reviewed and accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Key product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™, all of which are marketed under the BioStem umbrella.
For investors and industry observers, the presentation offers an opportunity to gain insights into BioStem's strategic direction, clinical research initiatives, and market expansion plans. The company has been actively pursuing innovation in regenerative medicine, a field that holds promise for addressing unmet medical needs in wound care, surgical repair, and other areas. By presenting at LD Micro, BioStem aims to highlight its differentiation through proprietary processing technologies that maintain the biological activity of its allografts.
Interested parties can follow the latest developments from BioStem by signing up for the company's email distribution list here, and by following the company on X and LinkedIn. The company's newsroom, accessible at https://tinyurl.com/bsemnewsroom, provides updates on $BSEM. As BioStem continues to advance its pipeline and commercial reach, its presentation at the LD Micro Invitational represents a key moment to communicate its value proposition to the investment community.